Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Capital Expenditures (2016 - 2024)

Arcadia Biosciences (RKDA) has disclosed Capital Expenditures for 11 consecutive years, with $3000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Capital Expenditures fell 40.0% year-over-year to $3000.0, compared with a TTM value of $3000.0 through Mar 2025, down 83.33%, and an annual FY2024 reading of $16000.0, up 220.0% over the prior year.
  • Capital Expenditures was $3000.0 for Q2 2024 at Arcadia Biosciences, down from $13000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $971000.0 in Q2 2020 and bottomed at -$2.0 million in Q4 2020.
  • Average Capital Expenditures over 5 years is $83642.9, with a median of $33000.0 recorded in 2022.
  • Peak annual rise in Capital Expenditures hit 1284.15% in 2020, while the deepest fall reached 233.72% in 2020.
  • Year by year, Capital Expenditures stood at -$2.0 million in 2020, then skyrocketed by 104.47% to $88000.0 in 2021, then crashed by 70.45% to $26000.0 in 2022, then plummeted by 80.77% to $5000.0 in 2023, then tumbled by 40.0% to $3000.0 in 2024.
  • Business Quant data shows Capital Expenditures for RKDA at $3000.0 in Q2 2024, $13000.0 in Q1 2024, and $5000.0 in Q2 2023.